TRX 818

Drug Profile

TRX 818

Alternative Names: CVM-1118; TRX-818

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TaiRx
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Growth inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 02 Jun 2017 Initial efficacy, safety and pharmacokinetics data from two phase I trials in Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Mar 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in Taiwan (PO) (NCT02703298)
  • 29 Jul 2015 TaiRx plans phase I trials in Cancer in USA (NCT02507544)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top